{
    "2019-01-14": [
        [
            {
                "time": "",
                "original_text": "天坛生物: q4收入正常, 血制品继续稳健增长",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "Q4",
                        "收入",
                        "血制品",
                        "稳健增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "13家公司新闻现重大利空",
                "features": {
                    "keywords": [
                        "13家公司",
                        "新闻",
                        "重大利空"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【医药-马帅】天坛生物业绩预告点评：Q4费用确认比较多，调浆获批产能利用率提升",
                "features": {
                    "keywords": [
                        "医药",
                        "天坛生物",
                        "业绩预告",
                        "Q4",
                        "费用确认",
                        "调浆获批",
                        "产能利用率",
                        "提升"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}